The Evolution of Radiotherapy in Children's Oncology Group Trials, from 1998-2025.
Analysis of IROC metadata from 8,898 patients across 83 Children's Oncology Group trials documents the replacement of 3D conformal photon radiotherapy by IMRT/VMAT and increasing proton radiotherapy use from 1998–2025, with greater than 90% protocol compliance across modalities.
Open original publication →What the AI sees
Analysis of IROC metadata from 8,898 patients across 83 Children's Oncology Group trials documents the replacement of 3D conformal photon radiotherapy by IMRT/VMAT and increasing proton radiotherapy use from 1998–2025, with greater than 90% protocol compliance across modalities.
Research significance
The record demonstrates adoption and feasibility of more conformal radiotherapy modalities; it is reasonable but unproven from these descriptive data to hypothesize that improved targeting with IMRT/VMAT or proton therapy could reduce late toxicity while preserving tumor control in selected pediatric cancers.
Source abstract
PURPOSE: Significant advancements in external beam radiotherapy (RT) over the past 20+ years have occurred with evolution from 2D techniques based on plain film x-rays to three-dimensional (3D) conformal and intensity modulated photon techniques. Likewise, proton radiotherapy (PRT) was also introduced and has become more widely available. Each advance in radiation technique improves targeting and has the potential to mitigate late effects associated with RT. In this study, we use metadata from past and present Children's Oncology Group (COG) trials that included RT to describe the evolution of different RT modalities across time and disease sites. METHODS: Imaging and Radiation Oncology Core (IROC) database was queried for protocols with at least one patient receiving RT during 1998-2025. Protocol metadata including primary disease site, study timeline and quality assurance (QA) was extracted, as was non-identifiable patient-level variables including age, institution, year of enrollment, and RT modality utilized. Descriptive statistics were used for downstream analysis. RESULTS: The study population comprised 8,898 patients, including 7,881 from the USA and 1,017 from other countries. The median age at enrollment was 9 years; California, Texas, Florida and New York were among the top contributing states. Of the 83 included COG trials, 48 included at least one patient receiving PRT. The number of trials allowing PRT peaked in 2010 with 17 protocols. Trials involving central nervous system (CNS) tumors and rhabdomyosarcoma soft tissue sarcomas (RST) dominated both in the number of trials and enrollment. They were also among the earliest to incorporate PRT into treatment protocols. From 1998 to 2025, 3D photon-based treatments declined from 73% to 15%, while IMRT/VMAT usage rose from 26% to 89% over the same interval. The use of PRT increased from 2% pre-2000 to nearly 40% in 2021, which has since stabilized. QA review demonstrated >90% protocol compliance across all RT modalities both nationally and internationally. CONCLUSIONS: Over 25 years of COG experience, photon therapy has transitioned from 3D conformal to IMRT/VMAT, while PRT use has continued to expand, particularly in CNS and RST trials. These trends highlight how pediatric cooperative-group studies continue to shape national standards and underscore the need for future work linking modality adoption with toxicity, survivorship, and access across diverse treatment settings.